Matthew J Lennon1,2, Steve R Makkar1,2, John D Crawford1,2, Perminder S Sachdev1,2,3. 1. School of Medicine, University of New South Wales, NSW, Australia. 2. Centre for Healthy Brain Aging, University of New South Wales, NSW, Australia. 3. Department of Neuropsychiatry, Prince of Wales Hospital, NSW, Australia.
Abstract
BACKGROUND: Hypertension is an established risk factor for stroke and vascular dementia but recent meta-analyses examining the association between Alzheimer's disease (AD) and hypertension have found no significant association. These meta-analyses included short term studies starting in late life which may have obscured the real effect of midlife hypertension. OBJECTIVE: To examine the association of AD with midlife hypertension, by including only studies with a sufficiently long follow up duration. METHODS: Relevant studies were found by searches of MEDLINE, EMBASE, and PubMed. Study outcomes were grouped by measures of blood pressure and definition of hypertension (e.g., systolic hypertension > 140 mmHg or > 160 mmHg). We assessed pooled effect estimates using random effects models and heterogeneity of pooled estimates through the I2 statistic. RESULTS: Literature search found 3,426 publications of which 7 were eligible studies. There was a significant association between systolic hypertension (>160 mm Hg) and AD (HR 1.25, 95CI 1.06 - 1.47, p = 0.0065). Similarly, for systolic hypertension > 140 mm Hg, there was a smaller but still significant association (HR 1.18, 95CI 1.02 - 1.35, p = 0.021). For diastolic hypertension, all four studies found no significant associations between diastolic hypertension and AD, and these data could not be pooled due to heterogeneity in reporting. CONCLUSIONS: Our study found that midlife stage 1 and stage 2 systolic hypertension is associated with increased risk of AD by 18 and 25%, respectively, although no association was found for diastolic hypertension. It is likely that assertive control of systolic hypertension starting in midlife is important to preventing AD.
BACKGROUND:Hypertension is an established risk factor for stroke and vascular dementia but recent meta-analyses examining the association between Alzheimer's disease (AD) and hypertension have found no significant association. These meta-analyses included short term studies starting in late life which may have obscured the real effect of midlife hypertension. OBJECTIVE: To examine the association of AD with midlife hypertension, by including only studies with a sufficiently long follow up duration. METHODS: Relevant studies were found by searches of MEDLINE, EMBASE, and PubMed. Study outcomes were grouped by measures of blood pressure and definition of hypertension (e.g., systolic hypertension > 140 mmHg or > 160 mmHg). We assessed pooled effect estimates using random effects models and heterogeneity of pooled estimates through the I2 statistic. RESULTS: Literature search found 3,426 publications of which 7 were eligible studies. There was a significant association between systolic hypertension (>160 mm Hg) and AD (HR 1.25, 95CI 1.06 - 1.47, p = 0.0065). Similarly, for systolic hypertension > 140 mm Hg, there was a smaller but still significant association (HR 1.18, 95CI 1.02 - 1.35, p = 0.021). For diastolic hypertension, all four studies found no significant associations between diastolic hypertension and AD, and these data could not be pooled due to heterogeneity in reporting. CONCLUSIONS: Our study found that midlife stage 1 and stage 2 systolic hypertension is associated with increased risk of AD by 18 and 25%, respectively, although no association was found for diastolic hypertension. It is likely that assertive control of systolic hypertension starting in midlife is important to preventing AD.
Authors: Alice Taubes; Phil Nova; Kelly A Zalocusky; Idit Kosti; Mesude Bicak; Misha Y Zilberter; Yanxia Hao; Seo Yeon Yoon; Tomiko Oskotsky; Silvia Pineda; Bin Chen; Emily A Aery Jones; Krishna Choudhary; Brian Grone; Maureen E Balestra; Fayzan Chaudhry; Ishan Paranjpe; Jessica De Freitas; Nicole Koutsodendris; Nuo Chen; Celine Wang; William Chang; Alice An; Benjamin S Glicksberg; Marina Sirota; Yadong Huang Journal: Nat Aging Date: 2021-10-11
Authors: Ronald M Lazar; Virginia J Howard; Walter N Kernan; Hugo J Aparicio; Deborah A Levine; Anthony J Viera; Lori C Jordan; David L Nyenhuis; Katherine L Possin; Farzaneh A Sorond; Carole L White Journal: Stroke Date: 2021-03-15 Impact factor: 7.914
Authors: Aaron Y Lai; Illsung L Joo; Arunachala U Trivedi; Adrienne Dorr; Mary E Hill; Bojana Stefanovic; JoAnne McLaurin Journal: Brain Res Date: 2021-02-12 Impact factor: 3.252
Authors: Oliver Bracko; Jean C Cruz Hernández; Laibaik Park; Nozomi Nishimura; Chris B Schaffer Journal: J Cereb Blood Flow Metab Date: 2021-01-14 Impact factor: 6.200